NVision Secures $55M Series B to Pivot from Quantum Sensing to Computing

NVision Secures $55M Series B to Pivot from Quantum Sensing to Computing NVision has completed a $55 million Series B financing round, bringing its total capital to $120 million. The round was anchored by Abbott, acting as the sole strategic diagnostics investor, and included a $17 million venture loan from the European Investment Bank (EIB) with participation from Playground Global, Matterwave/b2ventures, and Entrée Capital. Parallel to the funding, NVision announced a strategic expansion from quantum-enhanced sensing into quantum computing. This shift is intended to establish a “compute and validate” workflow, utilizing quantum computation for drug candidate design and quantum sensing for biological validation. POLARIS Quantum Sensing Platform and Clinical Deployment NVision’s established platform, POLARIS, utilizes Parahydrogen-Induced Polarization (PHIP) to enhance the MRI signal of metabolic agents, such as carbon-13 labeled pyruvate, by factors exceeding 10,000x. This gain in sensitivity allows standard MRI systems to perform real-time metabolic imaging, enabling the assessment of treatment efficacy within hours or days based on disease biology rather than structural changes. The hardware is designed for clinical environments, requiring no specialized quantum expertise or cryogenic infrastructure beyond standard medical facilities. By the end of 2026, NVision expects to deploy POLARIS systems across 20 research and clinical centers globally, including Memorial Sloan Kettering, the University of Cambridge, and the Technical University of Munich. Technical Architecture of Photonic Integrated Quantum Circuits (PIQC) The expansion into quantum computing is centered on a new architecture termed Photonic Integrated Quantum Circuits (PIQC). This platform utilizes a discovered class of organic molecule-based qubits that function as single-photon emitters. The technical design involves integrating a thin organic molecular layer directly onto photonic chips, a method compatible with standard semiconductor manufacturing processes. This approach is intended to provide a scalable path for quantum hardware by combining the coherent properties of molecular spins with established integrated photonic hardware. The PIQC platform is specifically targeted at simulating complex biological systems and accelerating the identification of drug candidates for previously inaccessible therapeutic targets. You can find the official announcement regarding NVision’s Series B and PIQC launch here. For more on the POLARIS sensing platform’s clinical applications, visit the technical overview here. May 13, 2026 Mohamed Abdel-Kareem2026-05-13T11:06:37-07:00 Leave A Comment Cancel replyComment Type in the text displayed above Δ This site uses Akismet to reduce spam. Learn how your comment data is processed.